FY2027 Earnings Forecast for Lexicon Pharmaceuticals, Inc. Issued By Leerink Partnrs (NASDAQ:LXRX)

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) – Analysts at Leerink Partnrs raised their FY2027 earnings per share (EPS) estimates for shares of Lexicon Pharmaceuticals in a note issued to investors on Friday, May 3rd. Leerink Partnrs analyst R. Ruiz now expects that the biopharmaceutical company will post earnings of $0.10 per share for the year, up from their prior estimate of $0.07. Leerink Partnrs has a “Outperform” rating on the stock. The consensus estimate for Lexicon Pharmaceuticals’ current full-year earnings is ($0.66) per share.

A number of other research firms also recently issued reports on LXRX. SVB Leerink initiated coverage on Lexicon Pharmaceuticals in a research note on Tuesday, April 30th. They set an “outperform” rating and a $5.00 price target for the company. StockNews.com upgraded shares of Lexicon Pharmaceuticals to a “sell” rating in a research report on Wednesday, May 1st. Finally, Needham & Company LLC reissued a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Friday.

Lexicon Pharmaceuticals Trading Up 2.4 %

NASDAQ:LXRX opened at $1.74 on Monday. The company has a 50 day simple moving average of $2.10 and a two-hundred day simple moving average of $1.75. The company has a market cap of $428.46 million, a PE ratio of -2.10 and a beta of 1.38. The company has a current ratio of 5.60, a quick ratio of 5.58 and a debt-to-equity ratio of 1.07. Lexicon Pharmaceuticals has a 12 month low of $0.92 and a 12 month high of $3.79.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its quarterly earnings data on Monday, March 11th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.03. The firm had revenue of $0.70 million during the quarter, compared to analysts’ expectations of $0.68 million. Lexicon Pharmaceuticals had a negative net margin of 8,311.12% and a negative return on equity of 137.53%.

Institutional Investors Weigh In On Lexicon Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Cantor Fitzgerald L. P. bought a new position in shares of Lexicon Pharmaceuticals in the fourth quarter worth approximately $25,000. TIAA Trust National Association purchased a new position in shares of Lexicon Pharmaceuticals during the 3rd quarter valued at $29,000. Principal Securities Inc. bought a new position in Lexicon Pharmaceuticals in the 4th quarter worth $33,000. Commonwealth Equity Services LLC increased its stake in Lexicon Pharmaceuticals by 160.9% in the 3rd quarter. Commonwealth Equity Services LLC now owns 39,569 shares of the biopharmaceutical company’s stock worth $43,000 after buying an additional 24,400 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its holdings in Lexicon Pharmaceuticals by 350.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 28,329 shares of the biopharmaceutical company’s stock valued at $43,000 after acquiring an additional 22,043 shares during the period. Institutional investors own 74.70% of the company’s stock.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.